Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Novel Targets in Drug Discovery' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Rheumatoid Arthritis: Emerging drug discovery targets And therapeutic candidates |
October 2003 | £375 | 100 % |
|
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets |
August 2004 | £425 | 97 % |
|
Biomedical Imaging From Drug Target Discovery to Medical Diagnostics |
December 2008 | £2290 | 70 % |
|
Drug Discovery Strategies and Methods |
November 2003 | £100 | 50 % |
|
Industrialization of Drug Discovery |
May 2005 | £80 | 39 % |
|
Drugs: From Discovery to Approval 2nd Edition |
January 2004 | £43.5 | 35 % |
|
Ion Channel Drug Discovery Therapeutic Opportunities & Technology Progress |
May 2004 | £855 | 32.2 % |
|
Ion Channel Trends 2007 |
June 2007 | £1540 | 27.3 % |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £2195 | 27 % |
|
Strategic Outlook on Protein Kinase Inhibitors in Oncology |
February 2006 | £1670 | 26.95 % |
|
Cancer Stem Cells Emerging Therapeutic, Diagnostic and Market Opportunities (2008) |
June 2008 | £1600 | 25.2 % |
|
Decoding Big Pharma's R&D Strategy in Oncology |
September 2007 | £1680 | 25.2 % |
|
AAIPharma Inc. - Strategic Analysis Review |
March 2009 | £76 | 25 % |
|
Albany Molecular Research, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 24 % |
|
Medicinal Chemistry for Drug Discovery Significance of Recent Trends |
March 2009 | £2290 | 23.8 % |
|
Neurogen Corporation - Financial and Strategic Analysis Review |
June 2009 | £76 | 23.5 % |
|
deCODE genetics, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 23.5 % |
|
Lexicon Pharmaceuticals Inc Premium Company Profile |
April 2008 | £265 | 23.5 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £685 | 23.5 % |
|
Avexa Limited - Financial and Strategic Analysis Review |
April 2009 | £76 | 23 % |
|
Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
July 2008 | £2005 | 23 % |
|
Infinity Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 22.5 % |
|
Isis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 21.5 % |
|
Uniting R&D and Marketing for Integrated Early-Stage Market Preparation |
May 2007 | £2010 | 21.5 % |
|
EPIX Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 21.5 % |
|
Biota Holdings Ltd. - Financial and Strategic Analysis Review |
April 2009 | £76 | 21.5 % |
|
Rigel Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 21.5 % |
|
Biotechnology and Biopharmaceuticals Transforming Proteins and Genes into Drugs |
July 2003 | £55.95 | 21.35 % |
|
Burger's Medicinal Chemistry and Drug Discovery 6 Volume Set |
March 2003 | £1730 | 21 % |
|
Global Market for Antimicrobials and Antifungals; The Challenging Resistance to 2016 |
December 2006 | £1600 | 21 % |
|
Drug Repositioning A market analysis |
March 2006 | £1095 | 20.65 % |
|
Alexion Pharmaceuticals - Financial and Strategic Analysis Review |
June 2009 | £76 | 20.5 % |
|
CombiMatrix Corporation - Financial and Strategic Analysis Review |
June 2009 | £76 | 20.5 % |
|
Supergen Inc Premium Company Profile |
December 2007 | £265 | 20.5 % |
|
Premium Company Profile: Invitrogen Corporation |
November 2007 | £265 | 20 % |
|
Cell-Based Assays for Drug Discovery |
January 2009 | £2075 | 19.95 % |
|
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology |
December 2006 | £4440 | 19.95 % |
|
Drug Discovery Tools for High-Content Analysis |
July 2007 | £1220 | 19.6 % |
|
Idera Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 19.5 % |
|
NeoPharm, Inc. - Financial and Strategic Analysis Review |
April 2009 | £76 | 19.5 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
May 2009 | £1525 | 19.5 % |
|
Outsourcing in Drug Discovery, 3rd Edition |
May 2008 | £1825 | 19.25 % |
|
Drug Repositioning Strategies Innovative Strategies To Boost Pipeline Productivity |
June 2007 | £1495 | 19.25 % |
|
Approaches to Reducing Phase II Attrition |
May 2009 | £2290 | 19.25 % |
|
GE Healthcare - Strategic Analysis Review |
June 2009 | £76 | 19 % |
|
GPCRs: Dawn of a New Era? |
October 2008 | £2290 | 18.9 % |
|
Cell Based Label-Free Detection Trends 2007 |
January 2008 | £1540 | 18.55 % |
|
Pharmacogenomics: The Search for Individualized Therapies |
April 2002 | £65 | 18.55 % |
|
Myriad Genetics, Inc. - Financial and Strategic Analysis Review |
April 2009 | £76 | 18.5 % |
|
A Practical Guide to Biopharmaceutical Manufacturing |
January 2006 | £1095 | 18.5 % |
|
Protein Kinase C (PKC) Inhibitors Competitor Analysis |
January 2009 | £170 | 18.5 % |
|
Market Development in Anti-virals What is Next? |
August 2004 | £425 | 18.2 % |
|
Millipore Corporation - Financial and Strategic Analysis Review |
June 2009 | £76 | 18 % |
|
Arpida Ltd. - Financial and Strategic Analysis Review |
June 2009 | £76 | 18 % |
|
Personalized Medicine Scientific & Commercial Aspects |
May 2009 | £2440 | 18 % |
|
Lorus Therapeutics Inc - Financial and Strategic Analysis Review |
April 2009 | £76 | 18 % |
|
Accelrys, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 18 % |
|
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology |
December 2006 | £2960 | 17.85 % |
|
Ariad Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 17.5 % |
|
Cytokinetics, Inc - Financial and Strategic Analysis Review |
June 2009 | £76 | 17.5 % |
|
CV Therapeutics, Inc - SWOT Analysis |
September 2008 | £66 | 17.5 % |
|
Commercial Opportunities from Biomarkers Transforming drug discovery, clinical development and molecular diagnostic |
May 2006 | £1495 | 17.5 % |
|
Antisense Therapeutics Limited - Financial and Strategic Analysis Review |
April 2009 | £76 | 17.5 % |
|
Cancer Biomarkers: Adoption Is Driving Growth |
July 2008 | £2290 | 17.5 % |
|
200 China-based Best CROs and CMOs |
March 2009 | £915 | 17.5 % |
|
Beckman Coulter, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 17.5 % |
|
Biochips Industry forecasts for 2012 & 2017 |
October 2008 | £2805 | 17.5 % |
|
ACADIA Pharmaceuticals Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 17.5 % |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £2960 | 17.5 % |
|
Advanced Proteome Therapeutics Corp. - Financial and Strategic Analysis Review |
April 2009 | £76 | 17 % |
|
Addex Pharmaceuticals - Financial and Strategic Analysis Review |
June 2009 | £76 | 17 % |
|
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery Equipment, Technologies and Companies, 2006-2011 |
January 2007 | £1005 | 16.8 % |
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology |
August 2006 | £2960 | 16.5 % |
|
Drug Discovery Handbook |
July 2005 | £94.5 | 16.45 % |
|
Fluorescence Lifetime Trends 2007 |
March 2007 | £1540 | 16.45 % |
|
Evaluation of Current Service Capabilities of Chinese Pharmaceutical Outsourcing Service Industry |
May 2008 | £535 | 16.1 % |
|
SuperGen, Inc. - SWOT Analysis |
December 2008 | £66 | 16 % |
|
Plk-1 Inhibitors Competitor Analysis |
May 2009 | £86 | 16 % |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 | 15.75 % |
|
Combinatorx Incorporated Premium Company Profile |
December 2007 | £265 | 15.5 % |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 | 15.5 % |
|
Biotech 2010 |
June 2006 | £2960 | 15.5 % |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4245 | 15.4 % |
|
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies |
May 2006 | £2960 | 15.4 % |
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology |
August 2006 | £2960 | 15.4 % |
|
Blood-Brain Barrier Bridging Options for Drug Discovery and Development |
May 2008 | £685 | 14.7 % |
|
Infinity Pharmaceuticals Inc Premium Company Profile |
December 2007 | £265 | 14.5 % |
|
Inflammatory Directions Strategies for Six Diseases with Unmet Needs |
April 2008 | £685 | 14.5 % |
|
Next Generation Protein Engineering and Drug Design Strategies to boost efficacy and improve drug delivery |
February 2007 | £1495 | 14.5 % |
|
The Future of Metabolomics Building competitive advantage in drug discovery, clinical development and diagnostics |
August 2006 | £1495 | 14.35 % |
|
Innovations in Bioinformatics Emerging Tools for Drug Discovery and Development |
January 2008 | £1995 | 14.35 % |
|
Stakeholder Opinions Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies |
July 2008 | £3800 | 14.35 % |
|
Antibiotic R&D Resolving the Paradox between Unmet Medical Need and Commercial Incentive |
July 2008 | £2290 | 14.35 % |
|
Translational Medicine In Biopharmaceutical R&d Enabling R&d Optimization And Early Detection Of Potential Failures |
October 2007 | £1495 | 14.35 % |
|
Personalized Medicine |
August 2007 | £1220 | 14 % |
|
MicroRNAs Commercial Products on the Horizon |
March 2008 | £685 | 14 % |
|
Biomarkers: The Future of Next-Generation Drug R&D |
September 2008 | £1585 | 13.65 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 13.65 % |
|
Bioinformatics Opportunities Business models, trends and future challenges |
May 2004 | £2500 | 13.65 % |
|
From blockbuster to nichebuster Niche therapies drive future drugs growth and incentivize R&D investment over sales spending |
July 2006 | £1055 | 13.3 % |
|
RNA Interference for Drug R&D Applications, Alliances, Companies and WW Market to 2011 |
July 2007 | £1585 | 13.3 % |
|
Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics |
June 2007 | £1495 | 12.95 % |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 | 12.95 % |
|
Bioinformatics Technical Status and Market Prospects |
August 2005 | £2960 | 12.95 % |
|
Winning R&D Productivity Strategies Exploiting innovation, licensing and outsourcing opportunities |
October 2006 | £1495 | 12.95 % |
|
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends |
November 2007 | £7600 | 12.95 % |
|
Compound Management Trends 2008 |
July 2008 | £1540 | 12.6 % |
|
When Patients Become Plaintiffs A Primer on Drug and Medical Device Liability |
January 2006 | £1095 | 12.6 % |
|
When Patients Becomes Plaintiffs A Primer on Drug and Medical Device Liability |
October 2006 | £1095 | 12.6 % |
|
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development |
June 2004 | £855 | 12.6 % |
|
The World Market for Gynaecology 2007-2017 |
September 2007 | £3200 | 12.5 % |
|
Alzheimer's Disease Biomarkers, 2009 |
January 2009 | £1499 | 12.5 % |
|
Cardiovascular Biomarkers: Players, products and prospects (Volume III) |
August 2008 | £595 | 12.25 % |
|
RNAi Technologies, Markets and Companies |
May 2009 | £1830 | 12.25 % |
|
Future of RNAi Therapeutics, The Drug Pipelines and Prospects |
September 2008 | £1995 | 12.25 % |
|
Proteomics Technologies, Markets and Companies |
May 2009 | £2135 | 11.9 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 11.5 % |
|
Genomics World Markets |
May 2008 | £2075 | 11.2 % |
|
Protease Inhibitors Innovation Drives Drug Pipeline |
February 2009 | £2290 | 11.2 % |
|
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics |
April 2008 | £1930 | 10.85 % |
|
Early Toxicology Markets and Approaches |
June 2007 | £2130 | 10.85 % |
|
Bioinformatics Report The forecasts and future of the market 2006-2011 |
October 2006 | £1499 | 10.5 % |
|
Cytogenetics Technologies,Markets and Companies |
May 2009 | £1220 | 10.5 % |
|
Bioinformatics Markets Strategies, Business Models and Trends for the Future |
March 2009 | £2075 | 10.15 % |
|
China Pharma Outsourcing Market By 2015 |
January 2009 | £1065 | 10.15 % |
|
Comparison of Pharma Outsourcing between China and India |
July 2009 | £915 | 10 % |
|
How Drugs Are Developed 3rd Edition |
January 2007 | £1095 | 9.8 % |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 | 9.8 % |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 | 9.8 % |
|
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity R&D Strategies |
August 2007 | £7600 | 9.8 % |
|
Impact of Pharmacogenomics on Public Healthcare Policy Educating Patients, Payors and Healthcare Providers |
March 2008 | £1995 | 9.1 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £2960 | 9.1 % |
|
Biomarkers The Expanding Global Market |
November 2007 | £2960 | 9.1 % |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1030 | 9.1 % |
|
Antibiotics and Drug Resistance 2008 Drug Innovation and the Strategy to Combat - Antibiotic Resistance Mechanisms |
January 2008 | £1499 | 9.1 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2075 | 8.75 % |
|
RNA Interference Markets |
December 2008 | £2075 | 8.75 % |
|
Market for Bioengineered Protein Drugs; The |
January 2007 | £2960 | 8.75 % |
|
Microarray Markets |
September 2008 | £1220 | 8.4 % |
|
Antiviral Therapeutics Technologies,Markets and Companies |
May 2009 | £1830 | 8.05 % |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 | 8 % |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2075 | 7.7 % |
|
Medical Nanotechnology Markets |
September 2008 | £2075 | 7.7 % |
|
Streamlining Information in the Pharmaceutical Industry with PLM (Review Report) |
August 2007 | £1795 | 7.7 % |
|
Pharmacogenomics: New Technologies In the Development of Personalized Therapies |
August 2005 | £2960 | 7.35 % |
|
Pain Therapeutics Drugs, Markets and Companies |
May 2009 | £1830 | 7.35 % |
|
World Contract Research and Manufacturing Market, 2006-2011, The Trends in Outsourcing |
August 2006 | £1499 | 7.35 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1710 | 7.35 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1710 | 7.35 % |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £2000 | 7.35 % |
|
DNA Sequencing and PCR Markets |
July 2008 | £2075 | 6.65 % |
|
Modern Biopharmaceuticals Design, Development and Optimization, 4 Volumes |
September 2005 | £440 | 6.65 % |
|
Stem Cells Come of Age |
November 2008 | £2290 | 6.65 % |
|
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, 2007 |
April 2008 | £970 | 6.5 % |
|
Gene Expression Reagents Markets |
April 2007 | £1220 | 6.3 % |
|
Liquid Chromatography Markets (LC, HPLC and UHPLC) |
March 2003 | £2135 | 5.95 % |
|
Animal Biotechnology Technologies, Markets and Companies |
May 2009 | £1525 | 5.6 % |
|
Cell Therapy Technologies, Markets and Companies |
May 2009 | £2745 | 5.25 % |
|
Dynamic Antibody Industry |
August 2005 | £2960 | 4.9 % |
|
The Market for In Vitro Toxicology Testing |
March 2007 | £2960 | 4.9 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 4.55 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009 |
June 2008 | £260 | 3.5 % |
|
Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts 2009 to 2015 |
February 2009 | £2075 | 3.5 % |
|
World Market for Molecular Diagnostics, The |
January 2009 | £2435 | 3.5 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £260 | 3.5 % |
|
Boston Scientific Medical Device Company Intelligence Report |
October 2006 | £395 | 3.15 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
May 2009 | £2745 | 2.8 % |
